Synergism of buthionine sulfoximine and melphalan against neuroblastoma cell lines derived after disease progression

Medical and Pediatric Oncology

Volumn 35, Issue 6, 2000, Pages 659-662

  Anderson, Clarke P ^a,b   Keshelava, Nino ^a   Satake, Noriko ^a   Meek, William H ^a   Patrick Reynolds, C ^a,b  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Buthionine sulfoximine; Disease progression; Melphalan; Neuroblastoma cell lines; Synergism

Indexed keywords

BUTHIONINE SULFOXIMINE; GLUTATHIONE; MELPHALAN; PROTEIN P53;

ARTICLE; CANCER GROWTH; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; HUMAN; HUMAN CELL; NEUROBLASTOMA; PRIORITY JOURNAL;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, ALKYLATING; BUTHIONINE SULFOXIMINE; CHILD; DISEASE PROGRESSION; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; HUMANS; MELPHALAN; NEUROBLASTOMA; TUMOR CELLS, CULTURED;

EID: 0033653618     PISSN: 00981532     EISSN: None     Source Type: Journal    
DOI: 10.1002/1096-911X(20001201)35:6<659::AID-MPO38>3.0.CO;2-4     Document Type: Article

References (30)

1. Neuroblastoma
2. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas
3. Current aspects of biology, risk assessment, and treatment of neuroblastoma
4. Biology and treatment of neuroblastoma
5. Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival
6. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid
7. Treatment of poor-risk neuroblastoma patients with high-dose chemotherapy and autologous peripheral stein cell rescue
8. Drug resistance in human neuroblastoma cell lines correlates with clinical therapy
9. Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy
10. p53 mutations and loss of p53 function confer multidrug resistance in neuroblastoma
11. Modulation of glutathione
12. Augmentation of adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion
13. Potentiation of melphalan cytotoxicity in human ovarian cancer cell lines by glutathione depletion
14. Selective modulation of glutathione levels in human normal versus tumor cells and subsequent differential response to chemotherapy drugs
15. In vivo therapeutic potential of combination thiol depletion and alkylating chemotherapy
16. Depleticn of glutathione by buthionine sulfoximine is cytotoxic for human neuroblastoma cell lines via apoptosis
17. Buthionine sulphoximine alone and in combination with melphalan (L-pare) is highly cytotoxic for human neuroblastoma cell lines
18. Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: An attempt at modulation of glutathione
19. Phase I study of continuous-infusion E-S,R-buthionine sulfoximine with intravenous melphalan
20. Depletion of glutathione in normal and malignant human cells in vivo by buthionine sulfoximine: Clinical and biochemical results
21. Variable baseline gamma-glutamylcysteine synthetase messenger RNA expression in peripheral lnononuclear cells of cancer patients, and its induction by buthionine sulfoximine treatment
22. A novel 96-well plate cytotoxicity assay based on fluorescence digital imaging microscopy
23. A fluorescence digital image microscopy system for quantifying relative cell numbers in tissue culture plates
24. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: A rational approach to clinical protocol design
25. A simple generalized equation for the analysis of multiple inhibitions of Michaelis-Menten kinetic systems
26. Relationships between inhibition constants and fractional inhibition in enzyme-catalyzed reactions with different numbers of reactants, different reaction mechanisms, and different types and mechanisms of inhibition
27. Pharmacokinetics of high-dose intravenous melphalan in patients undergoing peripheral blood hematopoietic progenitor-cell transplantation
28. Pharmacokinetics of high dose melphalan
29. Buthionine sulfoximine (BSO) and mephalan (L-PAM) is active against recurrent neuroblastoma